The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK - PubMed (original) (raw)

. 2012 Nov;8(11):897-904.

doi: 10.1038/nchembio.1069. Epub 2012 Sep 16.

Yan Chen, Qian Zhang, Jia-jia Zhuang, Min Tian, Hang-zi Chen, Lian-ru Zhang, Hong-kui Zhang, Jian-ping He, Wei-jia Wang, Rong Wu, Yuan Wang, Chunfang Shi, Kai Yang, An-zhong Li, Yong-zhen Xin, Terytty Yang Li, James Y Yang, Zhong-hui Zheng, Chun-dong Yu, Sheng-Cai Lin, Chawnshang Chang, Pei-qiang Huang, Tianwei Lin, Qiao Wu

Affiliations

• PMID: 22983157
• DOI: 10.1038/nchembio.1069

The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK

Yan-yan Zhan et al. Nat Chem Biol. 2012 Nov.

Abstract

Liver kinase B1 (LKB1) has important roles in governing energy homeostasis by regulating the activity of the energy sensor kinase AMP-activated protein kinase (AMPK). The regulation of LKB1 function, however, is still poorly understood. Here we demonstrate that the orphan nuclear receptor Nur77 binds and sequesters LKB1 in the nucleus, thereby attenuating AMPK activation. This Nur77 function is antagonized by the chemical compound ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate (TMPA), which interacts with Nur77 with high affinity and at specific sites. TMPA binding of Nur77 results in the release and shuttling of LKB1 to the cytoplasm to phosphorylate AMPKα. Moreover, TMPA effectively reduces blood glucose and alleviates insulin resistance in type II db/db and high-fat diet- and streptozotocin-induced diabetic mice but not in diabetic littermates with the Nur77 gene knocked out. This study attains a mechanistic understanding of the regulation of LKB1-AMPK axis and implicates Nur77 as a new and amenable target for the design and development of therapeutics to treat metabolic diseases.

PubMed Disclaimer

Comment in

• Metabolic disorders: New avenue to AMPK activation.
  Crunkhorn S. Crunkhorn S. Nat Rev Drug Discov. 2012 Nov;11(11):830. doi: 10.1038/nrd3872. Epub 2012 Oct 12. Nat Rev Drug Discov. 2012. PMID: 23060266 No abstract available.

Similar articles

• Characteristics of Nur77 and its ligands as potential anticancer compounds (Review).
  Wu L, Chen L. Wu L, et al. Mol Med Rep. 2018 Dec;18(6):4793-4801. doi: 10.3892/mmr.2018.9515. Epub 2018 Sep 27. Mol Med Rep. 2018. PMID: 30272297 Free PMC article. Review.
• Molecular dynamics study of TMPA mediated dissociation of Nur77-LKB1 complex.
  Rungsung I, Rajagopalan M, Ramaswamy A. Rungsung I, et al. Comput Biol Chem. 2018 Oct;76:67-78. doi: 10.1016/j.compbiolchem.2018.06.002. Epub 2018 Jun 30. Comput Biol Chem. 2018. PMID: 29982165
• Ethyl 2-[2,3,4-Trimethoxy-6-(1-Octanoyl)Phenyl] Acetate (TMPA) Ameliorates Lipid Accumulation by Disturbing the Combination of LKB1 with Nur77 and Activating the AMPK Pathway in HepG2 Cells and Mice Primary Hepatocytes.
  Wang X, Li G, Guo C, Zhang J, Kong J, He J, Li F, Liu Y, Yang Y, Lu Z, Liu J. Wang X, et al. Diabetes Metab Syndr Obes. 2021 Oct 2;14:4165-4177. doi: 10.2147/DMSO.S321246. eCollection 2021. Diabetes Metab Syndr Obes. 2021. PMID: 34629883 Free PMC article.
• The orphan nuclear receptor NR4A1 promotes FcεRI-stimulated mast cell activation and anaphylaxis by counteracting the inhibitory LKB1/AMPK axis.
  Jin F, Li X, Deng Y, Timilshina M, Huang B, Kim DY, Chang JH, Ichinose H, Baek SH, Murakami M, Lee YJ, Chang HW. Jin F, et al. Allergy. 2019 Jun;74(6):1145-1156. doi: 10.1111/all.13702. Epub 2019 Jan 4. Allergy. 2019. PMID: 30565708
• Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders.
  Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M, Andreelli F. Viollet B, et al. Diabetes Metab. 2007 Dec;33(6):395-402. doi: 10.1016/j.diabet.2007.10.004. Epub 2007 Nov 7. Diabetes Metab. 2007. PMID: 17997341 Review.

Cited by

• Identification of a Binding Site for Unsaturated Fatty Acids in the Orphan Nuclear Receptor Nurr1.
  de Vera IM, Giri PK, Munoz-Tello P, Brust R, Fuhrmann J, Matta-Camacho E, Shang J, Campbell S, Wilson HD, Granados J, Gardner WJ Jr, Creamer TP, Solt LA, Kojetin DJ. de Vera IM, et al. ACS Chem Biol. 2016 Jul 15;11(7):1795-9. doi: 10.1021/acschembio.6b00037. Epub 2016 Apr 29. ACS Chem Biol. 2016. PMID: 27128111 Free PMC article.
• mPGES-2 blockade antagonizes β-cell senescence to ameliorate diabetes by acting on NR4A1.
  Zhong D, Wan Z, Cai J, Quan L, Zhang R, Teng T, Gao H, Fan C, Wang M, Guo D, Zhang H, Jia Z, Sun Y. Zhong D, et al. Nat Metab. 2022 Feb;4(2):269-283. doi: 10.1038/s42255-022-00536-6. Epub 2022 Feb 28. Nat Metab. 2022. PMID: 35228744
• Characteristics of Nur77 and its ligands as potential anticancer compounds (Review).
  Wu L, Chen L. Wu L, et al. Mol Med Rep. 2018 Dec;18(6):4793-4801. doi: 10.3892/mmr.2018.9515. Epub 2018 Sep 27. Mol Med Rep. 2018. PMID: 30272297 Free PMC article. Review.
• Flavonoids Quercetin and Kaempferol Are NR4A1 Antagonists and Suppress Endometriosis in Female Mice.
  Zhang L, Mohankumar K, Martin G, Mariyam F, Park Y, Han SJ, Safe S. Zhang L, et al. Endocrinology. 2023 Aug 28;164(10):bqad133. doi: 10.1210/endocr/bqad133. Endocrinology. 2023. PMID: 37652054 Free PMC article.
• NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration.
  Hedrick E, Lee SO, Doddapaneni R, Singh M, Safe S. Hedrick E, et al. Mol Cell Biol. 2016 Apr 15;36(9):1383-94. doi: 10.1128/MCB.00912-15. Print 2016 May. Mol Cell Biol. 2016. PMID: 26929200 Free PMC article.

References

1. 1. Nat Struct Mol Biol. 2008 Aug;15(8):865-7 - PubMed
2. 1. Circulation. 2008 Feb 19;117(7):952-62 - PubMed
3. 1. J Appl Physiol (1985). 1997 Jan;82(1):219-25 - PubMed
4. 1. EMBO J. 2003 Oct 1;22(19):5102-14 - PubMed
5. 1. Mol Endocrinol. 2011 Oct;25(10):1773-85 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • GlyGen glycoinformatics resource

• Miscellaneous

  • NCI CPTAC Assay Portal